Metformin in amnestic mild cognitive impairment: Results of a pilot randomized placebo controlled clinical trial

Journal of Alzheimer's Disease

Volumn 51, Issue 2, 2016, Pages 501-514

  Luchsinger, José A ^a   Perez, Thania ^a   Chang, Helena ^b   Mehta, Pankaj ^c   Steffener, Jason ^d   Pradabhan, Gnanavalli ^a,e   Ichise, Masanori ^a   Manly, Jennifer ^d   Devanand, Davangere P ^a,e   Bagiella, Emilia ^b  

^a Department of Medicine   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^d Vagelos College of Physicians and Surgeons   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Amnestic mild cognitive impairment; insulin; memory; metformin; randomized clinical trial

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLUORODEOXYGLUCOSE; METFORMIN; PLACEBO; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); GLUCOSE; NOOTROPIC AGENT; PEPTIDE FRAGMENT;

ADULT; AGED; AMNESIA; ARTICLE; BLOATING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLUCOSE TRANSPORT; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; OBESITY; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; BLOOD; BRAIN; COGNITIVE DYSFUNCTION; DIAGNOSTIC IMAGING; DRUG EFFECTS; FOLLOW UP; METABOLISM; MIDDLE AGED; OVERWEIGHT; PILOT STUDY; PSYCHOLOGIC TEST; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BRAIN; COGNITIVE DYSFUNCTION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; MALE; METFORMIN; MIDDLE AGED; NOOTROPIC AGENTS; OVERWEIGHT; PEPTIDE FRAGMENTS; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84961773449     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150493     Document Type: Article

References (64)

1. Alzheimer's, Association. (2014). 2014 Alzheimer's disease facts and figures. Alzheimers Dement 10, e47-e92.
2. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. (1989). Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262, 2551-2556.
3. Brookmeyer R, Gray S, Kawas C. (1998). Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342.
4. Selkoe DJ. (2000). The origins of Alzheimer disease: A is for amyloid. JAMA 283, 1615-1617.
5. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, MarkesberyWR(1997). Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277, 813-817.
6. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR Jr. (2009). Mild [1] Alzheimer's, Association. (2014). 2014 Alzheimer's disease facts and figures. Alzheimers Dement 10, e47-e92.
7. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. (1989). Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262, 2551-2556.
8. Brookmeyer R, Gray S, Kawas C. (1998). Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342.
9. Selkoe DJ. (2000). The origins of Alzheimer disease: A is for amyloid. JAMA 283, 1615-1617.
10. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, MarkesberyWR(1997). Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277, 813-817.
11. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR Jr. (2009). Mild quantified correction for the effects of education. Arch Neurol 49, 453-460.
12. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. (1997). Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2), S22-S32.
13. WeschlerD(1987)Wechsler Memory Scale-revised manual, Psychological Corporation, New York
14. FolsteinMF, Folstein SE, McHugh PR. (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
15. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST. (2000). Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12, 233-239.
16. Weschler D. (1981). Manual for the adult Weschler intelligence scale-Revised, Psychological Corporation, Harcourt Brace Jovanovich, Inc., New York
17. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl De. (1995). A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 36, 1238-1248.
18. Alexander GE, Chen K, Pietrini P, Rapoport SI, ReimanEM. (2002). Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies.AmJ Psychiatry 159, 738-745.
19. Signorini M, Paulesu E, Friston K, Perani D, Colleluori A, Lucignani G, Grassi F, Bettinardi V, Frackowiak RSJ, Fazio F. (1999). Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping. Neuroimage 9, 63-80.
20. The Diabetes Prevention Program Research, Group. (2003). Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 26, 977-980.
21. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC. (2009). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365.
22. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kemppainen N, Nagren K, Kim BC, TsuiW, De Leon MJ. (2008). Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35, 2169-2181.
23. Luchsinger JA, Tang MX, Miller J, Green R, Mehta PD, Mayeux R. (2007). Relation of plasma homocysteine to plasma amyloid beta levels. Neurochem Res 32, 775-781.
24. Chudyk A, Masiuk M, Myslak M, Domanski L, Sienko J, Sulikowski T, Machalinski B, Giedrys-Kalemba S. (2006). SolubleHLAclass I molecules exert differentiated influence on renal graft condition. Transplant Proc 38, 90-93.
25. Hawkins JR, Khripin Y, Valdes AM, Weaver TA. (2002). Miniaturized sealed-tube allele-specific PCR. Hum Mutat 19, 543-553.
26. Myakishev MV, Khripin Y, Hu S, Hamer DH. (2001). Highthroughput SNP genotyping by allele-specific PCR with universal energy-transfer-labeled primers. Genome Res 11, 163-169.
27. Tuan C-Y, Abbasi F, Lamendola C, McLaughlin T, Reaven G. (2003). Usefulness of plasma glucose and insulin concentrations in identifying patients with insulin resistance. Am J Cardiol 92, 606-610.
28. Ridker PM. (2004). High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: From concept to clinical practice to clinical benefit. Am Heart J 148, S19-S26.
29. Ridker PM. (2007). Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: Implications for longevity. Nutr Rev 65, S253-S259.
30. Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA. Association of C-reactive protein with cognitive impairment. Arch Neurol 67, 87-92.
31. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. (2009). 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374, 1677-1686.
32. Yki-Jarvinen H. (2004). Thiazolidinediones. N Engl J Med 351, 1106-1118.
33. DREAM. (Diabetes REduction Assessment with ramipril and rosiglitazone Medication). Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. (2006). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: Arandomised controlled trial. Lancet 368, 1096-1105.
34. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, JonesNP, Kravitz BG, Lachin JM, O'neill MC, Zinman B, Viberti G. (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355, 2427-2443.
35. Nathan DM, BerkwitsM(2007). Trials that matter: Rosiglitazone, ramipril, and the prevention of type 2 diabetes. Ann Intern Med 146, 461-463.
36. Nathan DM. (2007). Rosiglitazone and cardiotoxicity - weighing the evidence. N Engl J Med 357, 64-66.
37. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD. (2006). Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6, 246-254.
38. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S. (2005). Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry 13, 950-958.
39. Dunn CJ, Peters DH, Metformin. (1995). A review of its pharmacological properties and therapeutic use in noninsulin- dependent diabetes mellitus. Drugs 49, 721-749.
40. Tian J, Shi J, Bailey K, Lendon CL, Pickering-Brown SM, Mann DMA. (2004). Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75, 696-699.
41. The Diabetes Prevention Program Research, Group. (2005). Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54, 1566-1572.
42. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, for the Diabetes Prevention Program Research, Group. (2005). The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann Intern Med 142, 611-619.
43. Diabetes Prevention Program Research, Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346, 393-403.
44. Nathan DM. (2002). Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347, 1342-1349.
45. Park CR. (2001). Cognitive effects of insulin in the central nervous system. Neurosci Biobehav Rev 25, 311-323.
46. Watson GS, Craft S. (2004). Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 490, 97-113.
47. FarrisW, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-Amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167.
48. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. (2012). Beneficial effects of metformin and irbesartan on advanced glycation end products. (AGEs)-RAGE-induced proximal tubular cell injury. Pharmacol Res 65, 297-302.
49. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. (2012). Metformin inhibits advanced glycation end products. (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs. (RAGE). expression. Horm Metab Res 44, 891-895.
50. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF. (2009). Antidiabetic drug metformin. (GlucophageR). increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A 106, 3907-3912.
51. Imfeld P, Bodmer M, Jick SS, Meier CR. (2012). Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: A population-based case-control study. J Am Geriatr Soc 60, 916-921.
52. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis KA, Bush AI, Faux NG, Martins R, Szoeke C, Rowe C, Watters DA. (2013). Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 36, 2981-2987.
53. Li J, Deng J, ShengW, Zuo Z. (2012). Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptinresistant mice. Pharmacol Biochem Behav 101, 564-574.
54. Gupta A, Bisht B, Dey CS. (2011). Peripheral insulinsensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 60, 910-920.
55. Hsu CC, Wahlqvist ML, Lee MS, Tsai. HN Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 24, 485-493.
56. Mura T, Proust-Lima C, Jacqmin-Gadda H, Akbaraly TN, Touchon J, Dubois B, Berr C. (2014). Measuring cognitive change in subjects with prodromal Alzheimer's disease. J Neurol Neurosurg Psychiatry 85, 363-370.
57. Duff K, Lyketsos CG, Beglinger LJ, Chelune G, Moser DJ, Arndt S, Schultz SK, Paulsen JS, Petersen RC, McCaffrey RJ. (2011). Practice effects predict cognitive outcome in amnestic mild cognitive impairment. Am J Geriatr Psychiatry 19, 932-939.
58. Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, Gibbons LE. (2012). The Alzheimer's Disease Assessment Scale-Cognitive-Plus. (ADAS-Cog-Plus): An expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav 6, 489-501.
59. Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, Chow N, Kohannim O, Cummings JL, Thompson PM, ElashoffD(2013). Estimating sample sizes for pre-dementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging 34, 62-72.
60. Mayeux R, Honig LS, Tang M-X, Manly J, Stern Y, Schupf N, Mehta PD. (2003). Plasma Abeta40 and Abeta42 and Alzheimer's disease: Relation to age, mortality, and risk. Neurology 61, 1185-1190.
61. Jessen F, Wolfsgruber S, Wiese B, Bickel H, Mosch E, Kaduszkiewicz H, Pentzek M, Riedel-Heller SG, Luck T, Fuchs A, Weyerer S, Werle J, Van den Bussche H, Scherer M, Maier W, Wagner M. (2014). AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimers Dement 10, 76-83.
62. Ali S, Fonseca V. (2012). Overview of metformin: Special focus on metformin extended release. Expert Opin Pharmacother 13, 1797-1805.
63. Cohen J. (1988). Statistical Power Analysis for the Behavioral Sciences, Lawrence Erlbaum Associates, Hillsdale, NJ.
64. Berg L. (1988). Clinical Dementia Rating. (CDR). Psychopharmacol Bull 24, 637-639.